Dow Jones

38,686.32

1.51%

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

HSGX

Histogenics (HSGX)

Histogenics Corporation

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:HSGX

1 2 3 4 5 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
21/11/2019	06:00	GlobeNewswire Inc.	Entera Bio Establishes U.S. Headquarters and Announces Jonathan Lieber as Chief Financial Officer	NASDAQ:HSGX	Histogenics Corporation
12/11/2019	15:17	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:HSGX	Histogenics Corporation
08/11/2019	15:07	Edgar (US Regulatory)	Proxy Statement (definitive) (def 14a)	NASDAQ:HSGX	Histogenics Corporation
08/11/2019	06:36	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:HSGX	Histogenics Corporation
06/11/2019	07:56	Edgar (US Regulatory)	Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)	NASDAQ:HSGX	Histogenics Corporation
06/11/2019	05:01	Edgar (US Regulatory)	Notice of Effectiveness (effect)	NASDAQ:HSGX	Histogenics Corporation
28/10/2019	15:59	Edgar (US Regulatory)	Securities Registration Statement (simplified Form) (s-3/a)	NASDAQ:HSGX	Histogenics Corporation
15/10/2019	14:04	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:HSGX	Histogenics Corporation
07/10/2019	16:31	Edgar (US Regulatory)	Securities Registration Statement (simplified Form) (s-3)	NASDAQ:HSGX	Histogenics Corporation
07/10/2019	16:29	Edgar (US Regulatory)	Amended Current Report Filing (8-k/a)	NASDAQ:HSGX	Histogenics Corporation
07/10/2019	12:32	Edgar (US Regulatory)	Statement of Ownership (sc 13g)	NASDAQ:HSGX	Histogenics Corporation
04/10/2019	11:56	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:HSGX	Histogenics Corporation
02/10/2019	07:01	Edgar (US Regulatory)	Amended Statement of Beneficial Ownership (sc 13d/a)	NASDAQ:HSGX	Histogenics Corporation
26/09/2019	16:12	Edgar (US Regulatory)	Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)	NASDAQ:HSGX	Histogenics Corporation
26/09/2019	15:25	GlobeNewswire Inc.	Histogenics Corporation Announces Approval of Merger by Stockholders at Special Meeting	NASDAQ:HSGX	Histogenics Corporation
12/09/2019	08:15	GlobeNewswire Inc.	Histogenics Corporation Announces Adjournment of its Special Meeting to Thursday, September 26, 2019	NASDAQ:HSGX	Histogenics Corporation
11/09/2019	15:05	GlobeNewswire Inc.	Histogenics Corporation Announces Intent to Convene and Adjourn Its Special Meeting	NASDAQ:HSGX	Histogenics Corporation
02/08/2019	12:13	Edgar (US Regulatory)	Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)	NASDAQ:HSGX	Histogenics Corporation
27/06/2019	15:32	Edgar (US Regulatory)	Withdrawal of Registration Statement (rw)	NASDAQ:HSGX	Histogenics Corporation
14/06/2019	16:24	Edgar (US Regulatory)	Securities Registration: Business Combination (s-4)	NASDAQ:HSGX	Histogenics Corporation
08/04/2019	06:00	GlobeNewswire Inc.	Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing Novel...	NASDAQ:HSGX	Histogenics Corporation
22/03/2019	05:02	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:HSGX	Histogenics Corporation
14/02/2019	16:23	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:HSGX	Histogenics Corporation
12/02/2019	07:00	GlobeNewswire Inc.	Jonathan Lieber Joins Danforth Advisors as Managing Director	NASDAQ:HSGX	Histogenics Corporation
21/12/2018	15:05	GlobeNewswire Inc.	Histogenics and FDA Conclude Discussions Regarding NeoCart® Phase 3 Clinical Trial Data and Regulatory Pathway	NASDAQ:HSGX	Histogenics Corporation
29/11/2018	07:30	GlobeNewswire Inc.	Histogenics and FDA Continue to Discuss NeoCart® Phase 3 Clinical Trial Data and Potential Regulatory Pathway	NASDAQ:HSGX	Histogenics Corporation
08/11/2018	05:30	GlobeNewswire Inc.	Histogenics Corporation Announces Third Quarter 2018 Financial and Operating Results	NASDAQ:HSGX	Histogenics Corporation
01/11/2018	15:05	GlobeNewswire Inc.	Histogenics and FDA to Continue Discussions on NeoCart Phase 3 Clinical Trial Data and Potential Regulatory Pathway	NASDAQ:HSGX	Histogenics Corporation
25/10/2018	15:15	GlobeNewswire Inc.	Histogenics Corporation to Report Third Quarter 2018 Financial Results on November 8, 2018	NASDAQ:HSGX	Histogenics Corporation
18/10/2018	15:48	Edgar (US Regulatory)	Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)	NASDAQ:HSGX	Histogenics Corporation